GLP-1 Drugs Linked to Lower Obesity-Cancer Rates
Adults with Type 2 diabetes on GLP-1 medications had lower obesity-related cancer rates than those on insulin or sulfonylureas.
Updated on Nov. 8, 2026 in Diabetes

Live Poll
Would you consider a weight-loss drug partly for lowering future cancer risk?
A study published in JAMA Network Open compared obesity-related cancer risk among people with Type 2 diabetes who started GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Trulicity, with those who started other diabetes treatments. Patients who started GLP-1 drugs had lower rates of obesity-related cancers than those who started insulin or sulfonylureas, with the difference most visible among adults with less severe diabetes.
Why it matters
Obesity is linked to at least 13 types of cancer, so any drug class associated with lower cancer rates draws attention from patients and clinicians weighing treatment options. The findings add a possible long-term dimension to GLP-1 use beyond blood sugar and weight, though the study shows an association rather than proof that the drugs prevent cancer.
This observational study followed people with Type 2 diabetes over three-year and five-year periods and compared those who started GLP-1 medications with those who started other diabetes treatments. Lower obesity-related cancer rates were seen against insulin and sulfonylureas, particularly among adults with less severe diabetes, but the association was not consistent across all comparisons.
The players
JAMA Network Open
An open-access peer-reviewed medical journal published by the American Medical Association that publishes research across clinical medicine.
American Cancer Society
A national nonprofit focused on cancer research, prevention and patient support, which identifies obesity as a risk factor for at least 13 cancer types.
The details
GLP-1 medications mimic a gut hormone that helps regulate blood sugar and appetite, and the drugs studied include Ozempic, Wegovy, Mounjaro and Trulicity. Researchers tracked cancer outcomes in patients who began these drugs and compared them with patients who began insulin or sulfonylureas, older diabetes treatments. Because the study is observational, differences in patient health, weight and other factors can influence results, which is why the authors frame the findings as an association.
Timeline
Patients were followed over three-year and five-year periods in the study.
The study was published in JAMA Network Open, and NewsNation reported on it on November 7, 2026.
Health Landscape
Concern about obesity-linked cancers has grown alongside the rapid adoption of GLP-1 drugs for weight loss and diabetes care. This study adds to a growing body of research asking whether these medications offer benefits beyond glucose control and weight reduction.
If you have Type 2 diabetes, this study is worth raising with your doctor, especially if you are weighing GLP-1 medications against insulin or sulfonylureas. Your clinician can help you consider your full health picture, including weight, cancer screening history and blood sugar goals.
The takeaway
The study suggests an association between GLP-1 use and lower obesity-related cancer rates, not proof of prevention. Keep up with cancer screenings as recommended, and discuss any questions about diabetes medication choices with your physician.
Further reading
For more on how these treatments are used, see our Diabetes coverage.
Source note: This article includes information reported by NewsNation.
Live Poll
Would you consider a weight-loss drug partly for lowering future cancer risk?





